Objective:

2

To investigate the relationship between gene mutations and response to Compound Qinghuang Powder (复方青黄散

CQHP) in patients with myelodysplastic syndrome (MDS).

Methods:

2

Forty-three MDS patients after treatment with CQHP for 6 months were genotyped by ultra-deep targeted sequencing and the clinical data of patients were collected and the relationship between them was analyzed.

Results:

2

Up to 41.86% of patients harbored genet mutations

in most cases with more than one mutation. The most common mutations were in SF3B1

U2AF1

ASXL1

and DNMT3A. After treatment with CQHP

about 88.00% of patients no longer required blood transfusion

or needed half of prior transfusions.

Conlusion:

2

CQHP is an effective treatment for patients with MDS

especially those with gene mutations in SF3B1

DNMT3A

U2AF1

and/or ASXL1.